Aura Biosciences, Inc.·4

Jun 15, 4:31 PM ET

Bitetti Teresa Marie 4

Research Summary

AI-generated summary

Updated

Aura (AURA) Director Teresa Bitetti Receives RSUs & Option Grant

What Happened Teresa Marie Bitetti, a director of Aura Biosciences (AURA), received two equity awards on June 11, 2026: 15,000 restricted stock units (RSUs) and a 30,000-share derivative award (a stock option grant). Both awards were reported at $0 cost in the Form 4 filed on June 15, 2026. These are awards/grants (code A) rather than open-market purchases or sales.

Key Details

  • Transaction date: 2026-06-11; Form 4 filed: 2026-06-15 (filed within the two-business-day window).
  • Awards: 15,000 RSUs @ $0; 30,000-share option/derivative @ $0.
  • Reported dollar value: $0 for both grants (standard for awards where no cash was paid).
  • Shares owned following the reported transactions: not disclosed in this filing.
  • Vesting (per footnotes): Both the RSUs and the option will vest in full upon the earlier of (a) June 11, 2027 or (b) the next annual meeting of stockholders, and are subject to the reporting person’s continued service on the vesting date.

Context

  • RSUs: Each RSU represents the right to receive one share of common stock at vesting; no shares were issued immediately for cash.
  • Option/derivative: This is a grant of a stock option (a right to buy shares in the future) that becomes exercisable only after the vesting conditions are met. No exercise or sale occurred in this filing.
  • Interpretation: Awards are common compensation for directors and do not by themselves indicate buying or selling sentiment. They are typically intended to align directors' interests with shareholders and depend on continued service.